Literature DB >> 17786001

Glioblastoma multiforme following cranial irradiation and chemotherapy for acute lymphocytic leukaemia. Report of 3 cases.

R Menon1, D Muzumdar, A Shah, A Goel.   

Abstract

The most common secondary neoplasms which occur following cranial radiation therapy are sarcoma and meningioma. The occurrence of glioblastoma multiforme following radiation and chemotherapy in acute lymphocytic leukaemia (ALL) is rare. We report 3 cases of glioblastoma multiforme in children developing 11-72 months following completion of chemotherapy/radiotherapy for ALL. The exact cause for the development of glioblastoma multiforme following therapy for ALL is not clear. A genetic predisposition may be essential for the occurrence of such a highly malignant primary brain tumour in leukaemia patients, irrespective of radiation and/or chemotherapy. The pathogenesis and surgical management are discussed, and the literature on the subject is reviewed. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786001     DOI: 10.1159/000106385

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  4 in total

1.  Radiation-induced glioblastoma multiforme in a remitted acute lymphocytic leukemia patient.

Authors:  Daewon Joh; Bong Jin Park; Young Jin Lim
Journal:  J Korean Neurosurg Soc       Date:  2011-09-30

Review 2.  Radiation-induced gliomas: a comprehensive review and meta-analysis.

Authors:  Ryuya Yamanaka; Azusa Hayano; Tomohiko Kanayama
Journal:  Neurosurg Rev       Date:  2016-10-05       Impact factor: 3.042

Review 3.  Secondary glioma following acute lymphocytic leukemia: therapeutic implications.

Authors:  Ryuya Yamanaka; Azusa Hayano
Journal:  Neurosurg Rev       Date:  2016-05-10       Impact factor: 3.042

4.  Metachronous gliomas following cranial irradiation for mixed germ cell tumors.

Authors:  Akari Makidono; Nobuo Kobayashi; Yukihisa Saida; Atsushi Manabe; Jiro Kawamori; Koyu Suzuki
Journal:  Childs Nerv Syst       Date:  2009-02-27       Impact factor: 1.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.